Understanding IgE Responses in Allergic and Non-Allergic Conditions
On the Origin of Immunoglobulin E's: Elucidating the Immunological Mechanisms Underlying Mucosal IgE Responses in Type2 Disease
This study is trying to understand how the immune system produces IgE in people with allergic rhinitis and asthma to see how it differs from those without allergies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Ghent Academic / other |
| Drugs / interventions | dupilumab |
| Locations | 1 site (Ghent) |
| Trial ID | NCT06234761 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the immunological mechanisms that drive local IgE production in patients with allergic rhinitis and late-onset eosinophilic asthma. By collecting and analyzing samples from patients with chronic rhinosinusitis with nasal polyps and those with allergic rhinitis, the study seeks to elucidate the distinct pathways leading to IgE responses in these conditions. The research will utilize high-resolution single-cell sequencing to map the B cell subsets and their immune receptor profiles, providing insights into the role of IgE in disease etiology and the effects of dupilumab treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with nasal polyposis or allergic rhinitis.
Not a fit: Patients who have been treated with systemic corticosteroids in the last two months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of the mechanisms behind IgE-related diseases, potentially improving treatment strategies for patients.
How similar studies have performed: While the specific approach of mapping IgE B cell responses in this context may be novel, similar studies have shown promise in understanding type 2 inflammation mechanisms.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients with nasal polyposis - Exclusion Criteria: patients treated in the last 2 months with systemic corticosteroids \-
Where this trial is running
Ghent
- University Hospital Gent — Ghent, Belgium (Recruiting)
Study contacts
- Study coordinator: Philippe Gevaert, PHD
- Email: philippe.gevaert@ugent.be
- Phone: 003293322332
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.